Skip to main content
. 2018 Jan 11;9(11):9975–9991. doi: 10.18632/oncotarget.24160

Figure 4. Evaluation of ubiquitin-proteasome, ER stress, and apoptosis-related pathways after syringolog-1 treatment by immunoblot analysis.

Figure 4

(A–C) Two multiple myeloma (MM) cells, KMS-11 and OPM-2, and Btz-resistant cells, KMS-11/Btz and OPN-2/Btz, were incubated with 10 nM of syringolog-1 (Sy) or bortezomib (Btz) for 16 h, and subjected to the analysis of changes in ubiquitin-proteasome, ER stress, and apoptosis-related pathways. (D) Btz-resistant MM cell lines and their parental lines were similarly evaluated. (E) Analysis of cell cycle distribution before and after the 10 nM of syringolog-1 treatment for 16 h. A representative case of three independent experiments. (F) Comparison of the ratio in G2/M phase between the control and the treatment by 10 nM of syringolog-1 for 16 h in two MM cells. * represents statistically significant by Student’s t-test (p < 0.05).